Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys by Losen, Mario et al.
  
 University of Groningen
Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus
monkeys
Losen, Mario; Labrijn, Aran F.; van Kranen-Mastenbroek, Vivianne H.; Janmaat, Maarten L.;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Losen, M., Labrijn, A. F., van Kranen-Mastenbroek, V. H., Janmaat, M. L., Haanstra, K. G., Beurskens, F.
J., ... Parren, P. W. H. I. (2017). Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia
gravis in rhesus monkeys. Scientific Reports, 7, [992]. https://doi.org/10.1038/s41598-017-01019-5
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
1Scientific RepoRts | 7: 992  | DOI:10.1038/s41598-017-01019-5
www.nature.com/scientificreports
Hinge-deleted IgG4 blocker 
therapy for acetylcholine receptor 
myasthenia gravis in rhesus 
monkeys
Mario Losen  1, Aran F. Labrijn  2, Vivianne H. van Kranen-Mastenbroek3, Maarten L. 
Janmaat2, Krista G. Haanstra  4, Frank J. Beurskens2, Tom Vink2, Margreet Jonker4,5, Bert A. 
‘t Hart4,6, Marina Mané-Damas1, Peter C. Molenaar1, Pilar Martinez-Martinez1, Eline van der 
Esch1, Janine Schuurman  2, Marc H. de Baets1,7 & Paul W. H. I. Parren  2,5
Autoantibodies against ion channels are the cause of numerous neurologic autoimmune disorders. 
Frequently, such pathogenic autoantibodies have a restricted epitope-specificity. In such cases, 
competing antibody formats devoid of pathogenic effector functions (blocker antibodies) have the 
potential to treat disease by displacing autoantibodies from their target. Here, we have used a model 
of the neuromuscular autoimmune disease myasthenia gravis in rhesus monkeys (Macaca mulatta) 
to test the therapeutic potential of a new blocker antibody: MG was induced by passive transfer of 
pathogenic acetylcholine receptor-specific monoclonal antibody IgG1-637. The effect of the blocker 
antibody (IgG4Δhinge-637, the hinge-deleted IgG4 version of IgG1-637) was assessed using decrement 
measurements and single-fiber electromyography. Three daily doses of 1.7 mg/kg IgG1-637 (cumulative 
dose 5 mg/kg) induced impairment of neuromuscular transmission, as demonstrated by significantly 
increased jitter, synaptic transmission failures (blockings) and a decrease in the amplitude of the 
compound muscle action potentials during repeated stimulations (decrement), without showing 
overt symptoms of muscle weakness. Treatment with three daily doses of 10 mg/kg IgG4Δhinge-637 
significantly reduced the IgG1-637-induced increase in jitter, blockings and decrement. Together, these 
results represent proof-of principle data for therapy of acetylcholine receptor-myasthenia gravis with a 
monovalent antibody format that blocks binding of pathogenic autoantibodies.
Autoimmune disorders affect more than 5% of the general population, while for reasons that are poorly under-
stood, the incidence of these disorders is currently increasing. In recent years, autoimmune mechanisms have 
been discovered in many diseases of the nervous system as being responsible for both neurological as well as 
psychiatric symptoms. Currently available broad-spectrum immunosuppressive drugs are routinely used to treat 
different autoimmune diseases, but often cause serious side-effects while generally taking four to fifteen months 
before achieving clinical remission. Antigen-specific therapies offer the possibility to avoid general immunosup-
pression and its associated risk for infections.
Myasthenia gravis (MG) is one of the best-understood autoimmune disorders and is characterized by muscle 
weakness as a result of impaired neuromuscular transmission. This is caused by autoantibodies against postsynap-
tic membrane proteins at the neuromuscular junction (NMJ). In most MG patients (~85%), the auto-antibodies 
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are directed to the muscle nicotinic acetylcholine receptor (AChR)1 and induce loss of the AChR by means of 
complement-mediated lyses of the postsynaptic membrane2, 3 and cross-linking-induced degradation of the 
AChR (antigenic modulation)4. The muscle AChR is highly susceptible to antibody cross-linking for two reasons: 
First, the AChR is densely clustered5 and second, each AChR pentamer contains two identical alpha subunits, 
thus allowing cross-linking of various AChRs by bivalent antibodies against the alpha subunit. More than half of 
AChR-specific autoantibodies in MG patients is directed to the main immunogenic region (MIR) on the AChR 
alpha subunits6, as exemplified by the human monoclonal antibody IgG1-6377, 8. Although the MIR is important 
for expression and assembly of the AChR, MIR-specific autoantibodies do not interfere with AChR function, such 
as recognition of acetylcholine released from nerve terminals and opening of the receptor channel8. The exposed 
orientation of the MIRs of adjacent AChRs allows bivalent binding of MIR-antibodies, resulting in rapid AChR 
degradation. In contrast to the overall AChR antibody titer, the MIR antibody titer is strongly correlated to sever-
ity of muscle weakness in MG patients6. The pathogenicity and restricted epitope-specificity of AChR-specific 
autoantibodies makes the MIR an attractive target for blocker therapy with non-pathogenic antibodies9–11. 
Although autoantibodies can bind to various conformational epitopes within the MIR (e.g. 1–32 and 60–818) the 
binding area typically buried upon antibody binding is a circle with a diameter of 3.1 nm. Therefore, a blocking 
antibody has the potential to shield a large part of the AChR, which has a diameter of ~6 nm5. In passive transfer 
MG (PTMG) experiments using rats and mice, blocking antibody fragments directed against the MIR have been 
shown to prevent muscle weakness10, 12. In vitro, a single chain-Fv antibody fragment of IgG1–637 blocked bind-
ing of MG patient autoantibodies by 31.4% (range 2–77.4%)9. Similarly, varying degrees of competition of MG 
patients’ antibodies were observed with Fab-637 (ranging between <10% and 100%)7.
In rhesus monkeys, IgG1-637 causes destruction of the postsynaptic membrane, thereby inducing MG symp-
toms of muscle weakness11. In this model, an IgG4 version of the same antibody, IgG4-637, did not induce PTMG, 
and moreover, prevented IgG1-637-mediated muscle weakness11. This protective effect was explained by the ina-
bility of IgG4-637 to activate rhesus monkey complement, and the intrinsic ability of human IgG4 molecules to 
engage in Fab-arm exchange leading to functional monovalency; thus preventing antigenic modulation through 
cross-linking11, 13, 14.
Although these results are promising from a therapeutic point of view, Fab-arm exchange is a slow process in 
vivo11, 15, which implies that therapeutic IgG4 would only gradually become functionally monovalent and thus 
would initially be able to cause harmful cross-linking-induced antigenic modulation, directly when administered 
to patients or animals. Moreover, indirect cross-linking through residual interactions of IgG4 with Fcγ recep-
tors16–18 may represent an alternative route for antigenic modulation independent of functional monovalency. In 
addition, during Fab-arm exchange, bispecific antibodies will be generated with unknown partner-specificities, 
which may result in unpredictable pharmacodynamics. Taken together, these considerations suggest that for 
immunotherapy of MG an alternative antibody format with superior non-activating (no complement activa-
tion or Fcγ-receptor interaction) and non-cross-linking properties, compared to IgG4, is desired for clinical 
implementation.
In humans, the clinical presentation of AChR-MG may comprise fluctuating fatigability, drooping of eye-
lids (ptosis), difficulty in swallowing (dysphagia), shortness of breath (dyspnea) and proximal muscle weakness 
on repetitive use of the muscles19. Apart from the analysis of serum autoantibodies against the AChR, several 
functional tests are used for diagnosis, including injection of a cholinesterase inhibitor (Tensilon test), electro-
myography (EMG) and single-fiber electromyography (SFEMG). Of these tests, SFEMG is the most sensitive for 
detecting defects in neuromuscular transmission. In experimental autoimmune MG, rhesus monkeys display the 
same range of clinical symptoms as patients with MG (e.g. fatigability, hypoactivity, ptosis, dysphagia, anorexia), 
which can be scored by observing the behavior20, 21. Unlike in chronic models, in PTMG these symptoms are 
reversible and dose-dependent11.
In this study we evaluated hinge-deleted IgG4 (IgG4Δhinge) as therapeutic antibody format in PTMG in rhe-
sus monkeys. By employing diagnostic EMG and SFEMG, we could study the therapeutic effects in this animal 
model and show that IgG4Δhinge protected the NMJ against a myasthenogenic autoantibody.
Results
Generation and functional characterization of IgG4Δhinge-637. In order to increase the non-ac-
tivating and non-cross-linking properties of human IgG4, constructs lacking the genetic hinge exon were 
generated, resulting in hinge-deleted IgG4 (IgG4Δhinge) molecules (Fig. 1a). Especially the absence of inter 
heavy-chain disulfide linkages in IgG4Δhinge, as a result of C226 and C229 deletion, is thought to eliminate 
residual Fcγ receptor interactions, like observed for IgG1 and IgG322, 23. The hinge deletion in combination with 
the relatively weak CH3-CH3 interface interaction in human IgG4, minimizes heavy chain dimerization and thus 
antigen cross-linking24.
To study this, an IgG4Δhinge version of mAb 637 was constructed and compared to IgG1-637 and IgG4-637 
by non-reducing SDS-PAGE (Fig. 1b). Whereas IgG1-637 remained intact under non-reducing conditions, IgG4-
637 displayed a mixture of intact (H2L2) and half-molecules (HL), as is characteristic for monoclonal wild-type 
human IgG4 molecules25–27. As expected, deletion of the genetic hinge region resulted in an exclusive population 
of non-covalently linked half-molecules (modeled in Fig. 1c).
The inability of IgG4Δhinge to activate complement was confirmed by C1q-binding ELISA (Supplementary Fig. 1a) 
and complement dependent cytotoxicity (CDC) assay (Supplementary Fig. 1b) using an IgG4Δhinge version of 
HuMab 7D828, directed against the CD20 antigen and shown to potently induce CDC as IgG1. Furthermore, elimina-
tion of residual FcγRI receptor interaction of IgG4Δhinge was confirmed by flow-cytometry (Supplementary Fig. 1c). 
Together, these data show that IgG4Δhinge has superior non-activating properties compared to IgG4.
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Lack of inter heavy-chain disulfide linkage has been shown to influence antibody serum half-life29. Furthermore, 
as half-molecules contain only one instead of two binding sites for the neonatal Fc receptor (FcRn)30, their rescue 
from the IgG degradation pathway is likely to be impaired31. To determine the pharmacokinetics of IgG4Δhinge, 
single doses of IgG4-637 or IgG4Δhinge-637 were injected into Balb/c mice, cynomolgus monkeys (Macaca fascicu-
laris) and human FcRn transgenic (Tg) mice32 and serum levels were followed over time (Supplementary Fig. 2a–c). 
As anticipated, IgG4Δhinge-637 was cleared 2.5, 2 and 3.2 times faster compared to IgG4-637 in the respective 
animal models (Supplementary Fig. 2d). IgG4Δhinge-637, however, was still protected from catabolic degradation 
as shown by the much faster clearance of the F(ab’)2 fragments (Supplementary Fig. 2a,d).
Protection against auto-antibody-induced AChR down-modulation in vitro. Bivalent targeting 
of the AChR, by either IgG1-637 or IgG4-637, induced AChR surface down-modulation (antigenic modula-
tion) in vitro (Fig. 1d), as described4, 33–35. In contrast, IgG4Δhinge-637 did not reduce AChR surface expression, 
showing that IgG4Δhinge-637 is non-cross-linking (Fig. 1d). To investigate whether IgG4Δhinge-637 could 
protect against AChR surface down-modulation, serial dilutions of IgG4Δhinge-637 were co-incubated with a 
fixed optimal concentration of IgG1-637. Indeed, IgG4Δhinge-637 could effectively inhibit IgG1-637-mediated 
loss of AChR expression (Fig. 1e). Pooled intravenous immunoglobulin (IVIg), included as a negative control, 
did not affect AChR expression by itself, and no significant changes in AChR expression were observed when 
co-incubated with IgG4Δhinge-637 (Fig. 1e). These data showed that IgG4Δhinge-637 is able to neutralize IgG1-
637-mediated down modulation of the AChR in vitro and limited the loss of AChR expression.
Passive transfer MG and clinical evaluation in rhesus monkey model. Since establishment of the 
PTMG model11, improved animal housing conditions had resulted in increased weight, muscle mass and fitness 
of experimental rhesus monkeys. Therefore, a pilot study with six female rhesus monkeys was initiated in order 
to check the validity of the experimental conditions for monkeys raised under the new housing conditions. The 
animals were each challenged intravenously with 1.7 mg/kg/day IgG1-637 on three consecutive days, adding up to 
a cumulative dose of 5 mg/kg IgG1-637, which had been shown to result in clinical symptoms of MG in a previous 
study using lighter animals11. In the present study, neuromuscular transmission was investigated using single 
fiber electromyography (SFEMG), to increase sensitivity of the analysis. Furthermore, clinical observation, blood 
sampling, decrement measurements of the compound muscle action potential (CMAP) and intercostal biopsies 
were all included in the clinical evaluation.
Figure 1. Design and in vitro characterization of IgG4Δhinge. (a) Sequence alignment of residues 205–234 
(EU-numbering convention) of human IgG1, IgG4 and IgG4Δhinge. (b) Purified human IgG1, IgG4 and 
IgG4Δhinge variants of mAb 637 analyzed by non-reducing SDS-PAGE (image is cropped to show relevant 
bands, the complete gel is shown in supplementary Fig. 5). (c) In silico model of IgG4Δhinge based on crystal 
structures 1ADQ61 (CH2-CH3 domains), 1MCO62 (Δhinge region) and 1HZH63 (Fab region). HCΔhinge 
depicted in green, LC depicted in pale green. (d) AChR surface down-modulation on TE671 cells by purified 
variants of mAb 637 as indicated. Pooled intravenous immunoglobulin (IVIg) is included as negative control (e) 
Inhibition of (auto-) antibody-mediated AChR surface down-modulation on TE671 cells by IgG4Δhinge-637. 
Different concentrations of the challenge autoantibody (IgG1-637) or a negative control (IVIG) were tested in 
combination with IgG4Δhinge-637; each curve corresponds to a single concentration of challenge antibody 
(0–10 nM) as shown in the key on the right.
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Intravenous (i.v.) injections with IgG1-637 were well tolerated and no acute adverse effects were observed. 
Based on clinical observations, none of the animals showed muscle weakness. Baseline (before antibody treat-
ment) mean consecutive difference (MCD) or “jitter” values were recorded in these animals ranging from 9–19 µs 
(Supplementary Fig. 3), similar to those found in healthy humans (typically between 10 and 20 µs36, 37). Seven days 
after the first injection of the three daily doses of IgG1-637, the jitter values in the six rhesus monkeys increased 
significantly, with MCD values ranging from 39 to 130 μs (Supplementary Fig. 3).
As a considerable effect on jitter could be measured by SFEMG, without evident muscle weakness, the 5 mg/
kg IgG1-637 dose was chosen as a model for subclinical MG. Since jitter values above 91 μs are strongly predictive 
for respiratory muscle weakness in MG patients38, we considered it possible that moderate clinical symptoms 
were not observed due to the natural behavior of rhesus monkeys to avoid showing weakness in order to preserve 
social hierarchy39. No higher IgG1-637 dose was attempted for our studies to avoid the risk of inducing a myas-
thenic crisis. All other recorded data were blinded, included in the subsequent study and (re-) analyzed.
Electrophysiological evaluation of IgG4Δhinge-637 treatment in passive transfer MG. 
Subclinical MG was induced in seven additional animals to assess the therapeutic effect of IgG4Δhinge-637. For 
this, the animals received three daily intravenous doses of 10 mg/kg IgG4Δhinge-637 (n = 6) or PBS (n = 1), six 
hours prior to challenge with IgG1-637. The dosing of IgG4Δhinge-637 was based on the protective dose of IgG4-
637 (three daily doses of 5 mg/kg) in a previous study11, compensated for the two-fold faster clearance compared 
to IgG4 as determined in cynomolgus monkeys (Supplementary Fig. 2). Two additional control animals only 
received IgG4Δhinge-637 and no IgG1-637 challenge. Clinical signs of MG were monitored as described above 
(Fig. 2a).
Blinded (re-)analysis of the SFEMG data of the untreated rhesus monkeys (seven animals total) yielded con-
trol values for jitter in rhesus monkeys. The mean MCD obtained was 14.83 ± 3.39 μs (range 9–19 μs; Fig. 2B) with 
an upper limit (mean ± 3 SD) of 24.99 μs. The mean control MCD for all individual potentials (n = 352) obtained 
was 14.88 ± 6.45 μs (range 5–55 μs) with an upper limit of 34.23 μs. Administration of IgG4Δhinge-637 alone 
did not significantly increase the jitter (Fig. 2b). Challenge with IgG1–637 significantly (P < 0.001) increased the 
jitter compared to controls (Fig. 2b). Animals receiving IgG4Δhinge-637 treatment prior to pathogenic challenge 
with IgG1-637 showed significantly (P < 0.001) reduced jitter compared to the group challenged with IgG1-637 
alone (Fig. 2b).
Subsequently, we analyzed the frequency of neuromuscular blockings, the failure to elicit an action potential in 
the muscle fiber upon stimulation of the motor nerve (Fig. 2c). No blocking events were observed in the animals 
before antibody administration. A few events (4%) of blockings were observed in one out of two animals injected 
with the IgG4Δhinge-637 alone, indicating a possible minor effect on synaptic transmission. In six out of seven 
animals challenged with IgG1-637, blocking events were observed with an average blocking rate per animal of 
24.1% (Fig. 2c). Similarly, blocking was observed in five out of six rhesus monkeys treated with IgG4Δhinge-637 
Figure 2. Electrophysiological evaluation of IgG4Δhinge-637 treated rhesus monkeys. (a) Treatment schedule. 
Monkeys were treated with PBS or IgG4Δhinge-637 (IgG4Δhinge) on three consecutive days (T1-T3), 
6 hours prior to challenge (Ch1-Ch3) with PBS or IgG1-637 (IgG1). Intercostal muscle biopsies, single fiber 
electromyography (SFMG) and compound muscle action potential (CMAP) measurements during repetitive 
nerve stimulation were performed before (pre) and 7 days after start of treatment. Red arrowheads indicate 
blood sampling. Mean consecutive difference (MCD) of the delay between motor nerve stimulation and muscle 
fiber action potential (Jitter) (b) and neuromuscular transmission failures (Blockings) (c) in the orbicularis 
oculi muscle in different treatment groups. Decrement amplitude (d) and area (e) in the CMAP of the extensor 
digitorum brevis muscle in different treatment groups. Reference values were recorded before start of treatment 
(Pre). Data represent mean ± SEM.
www.nature.com/scientificreports/
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six hours prior to injection with IgG1-637. In these animals, the number of blockings induced by IgG1-637 was 
significantly (P < 0.0001) reduced to 8.6% by treatment with IgG4Δhinge-637 (Fig. 2c).
During repetitive nerve stimulation, the amount of neurotransmitter that is released at each subsequent nerve 
impulse decreases, especially at higher stimulation frequencies. In combination with low levels of AChRs, this 
leads to increasing numbers of neuromuscular blocking events during repetitive nerve stimulation. As a result, 
the CMAP decreases during repetitive stimulations of the muscles, which is referred to as a decrement of the 
CMAP response. In clinical practice a decrement of 10% or more at a stimulation frequency of 3 Hz (including 
both the amplitude and the area under the curve) is considered confirmation of the diagnosis of MG in indi-
vidual patients40. More recently, a 7–8% cutoff was found to increase sensitivity of this test for MG diagnosis by 
6–11%, while preserving high specificity of >95%41. CMAPs were recorded from the extensor digitorum brevis 
(EDB) muscle of the foot during repeated stimulation of the peroneal nerve below the fibular head. Four out 
of seven animals had 7% decrement or more in the untreated IgG1-637-challenged group (see Supplemental 
Table 2). None of the animals in the other experimental groups reached these levels. There were significant dif-
ferences of the average decrement values between the groups (Fig. 2d and e) that paralleled the aforementioned 
changes in jitter values (Fig. 2b). Amplitude and area decrement values measured in animals in the untreated 
and in the IgG4Δhinge-637 control groups ranged between −3% and +5%. Administration of IgG1-637 signif-
icantly increased average decrement values to 11% for amplitude and 13% for area decrement. Treatment with 
IgG4Δhinge-637 significantly reduced these IgG-637-induced decrement values to −0.3% and 1.4%, respectively 
(both P < 0.0001) (Fig. 2d and e).
Electron microscopic analysis of intercostal neuromuscular junctions. Electron micrographs were 
used for qualitative and quantitative evaluation of the degree of postsynaptic damage at synaptic boutons in inter-
costal muscle biopsies taken before, and one week after the first antibody administration (Fig. 3a–f). In line with 
the mild clinical symptoms, no significant differences of the folding index (a measure for folding complexity of 
Figure 3. Electron microscopic analyses of intercostal neuromuscular junctions in rhesus monkeys. 
Transmission electron micrographs showing representative nerve boutons of 3 animals, either before 
(‘Prescreening’, a,b,c) or seven days after challenge with IgG4Δhinge-637 (d), IgG1-637 (e) or the combination 
of IgG4Δhinge-637 and IgG1-637 (f). Each micrograph has the dimension of 5 × 6 µm. Asterisks indicate 
nerve terminals/boutons and arrowheads point at the (intact) primary synaptic clefts. Arrows point to normal 
secondary postsynaptic clefts/folds; the daggers in panel e indicate widening of the primary synaptic cleft, where 
the presynaptic and the postsynaptic membrane were separated from each other. (g) The folding index (length 
of postsynaptic membrane/length of the corresponding presynaptic membrane), a measure of the degree of 
postsynaptic folding. (h) Blinded scoring of the normal versus widened synaptic clefts.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 992  | DOI:10.1038/s41598-017-01019-5
the postsynaptic membrane) were observed between the experimental groups (Fig. 3g). Nonetheless, a widen-
ing of the primary and secondary synaptic cleft (indicating ultrastructural damage of the NMJ) was frequently 
observed (see Fig. 3e). Because no quantitative morphometric analysis is currently available for this change, all 
images were subjected to blind qualitative scoring (Fig. 3h). This indicated a significant widening of the primary 
synaptic cleft in the IgG1-637-challenged muscles as compared to the untreated control muscles. In contrast, sig-
nificant cleft widening was not observed in combination with the IgG4Δhinge-637 treatment (Fig. 3h).
Plasma and NMJ levels of active complement. In addition to antigenic modulation, the pathogenicity 
of IgG1-637 may be attributed to antibody-mediated complement activation. To investigate the role of comple-
ment in the PTMG model in rhesus monkey, levels of C4b/c, as a measure for overall complement activation, 
were quantified at different time-points in the plasma of all monkeys. No significant changes in C4b/c levels were 
observed in time or between groups (Supplementary Fig. 4). Moreover, we analyzed formation of membrane 
attack complex (MAC, C5b-9) in intercostal muscle biopsies taken before and after antibody treatment (Fig. 4). 
While little or no MAC staining was found in endplates of unchallenged and IgG4Δhinge-637-treated mon-
keys, a consistently very strong MAC staining colocalized with human IgG and alpha-bungarotoxin staining in 
IgG1-637-treated monkeys (Fig. 4a). Treatment with IgG4Δhinge-637 prevented MAC deposition in endplates 
of IgG1-637 challenged animals by 70% (P < 0.01) (Fig. 4b). Since total human IgG levels (IgG1 + IgG4Δhinge) 
were comparable between these groups (Fig. 4c), these data suggest that IgG4Δhinge partially blocked binding 
of IgG1 at the intercostal NMJs.
Discussion
The presence of circulating autoantibodies is a hallmark of autoimmune disease (AID). In some organ-specific 
AIDs, like MG, the autoantibodies are solely responsible for the elicitation of pathogenic effects and frequently 
display restricted epitope-specificity7, 42, 43. In such cases, displacing pathogenic autoantibodies from their target 
with blocker antibodies (competing antibody formats devoid of pathogenic effector functions) represents a poten-
tial treatment strategy. The validity of this concept has been demonstrated previously with MIR-specific antibody 
formats in AChR MG7, 11 and an aquaporin-4 (AQP4)-specific antibody format in neuromyelitis optica44.
In MG, the autoantibody-mediated pathogenic effector functions include antigenic modulation through 
auto-antibody-mediated receptor cross-linking4 and complement-mediated lysis of the post-synaptic mem-
brane2, 3. The therapeutic potential of Fab fragments and post-exchange IgG4 has been shown before7, 11, as both 
can displace pathogenic serum auto-antibodies without being able to activate complement or induce receptor 
cross-linking, due to their (functional) monovalency. However, the rapid clearance of Fab fragments from the 
circulation and the potential of IgG4 for indirect cross-linking via residual Fc-receptor interactions are clear dis-
advantages of these approaches16–18. In addition, IgG4 only gradually becomes functionally monovalent through 
Figure 4. Quantitative Immunofluorescent analysis of NMJ endplates in rhesus monkey intercostal 
biopsies. Biopsies were obtained from each animal before (“Pre”) or 7 days after antibody challenge with 
IgG4Δhinge-637, IgG1-637 or the combination of both. (a) Representative photomicrographs from the four 
groups showing staining of the AChR (detected by alpha-bungarotoxin fluorescence), IgG (IgG + IgG4Δhinge), 
the membrane attack complex (MAC) and a merged image to show colocalization. Relative fluorescence 
intensities (RFU) of (b) MAC staining and (c) human IgG staining was normalized with AChR expression in 
individual endplates. Intensities were quantitated in a total of 589 endplates (5-158 endplates per biopsy) and 
averaged per biopsy. The number n indicates the number of animals/biopsies analyzed for each condition. Data 
represent means ± SEM.
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Fab-arm exchange upon administration in patients and thus could be pathogenic by inducing cross-linking 
through bivalent interaction at the initiation of therapy11, 15. The present study describes the use of IgG4Δhinge 
as format for blocker therapy of MG in a non-human primate model. The patient-derived IgG4Δhinge blocked 
cell surface AChR binding of a pathogenic IgG1 and prevented antigenic modulation in vitro. Treatment of path-
ogenic IgG1-challenged rhesus monkeys with IgG4Δhinge significantly improved the neuromuscular transmis-
sion defects in vivo as measured by electromyography and microscopic analysis of muscle biopsies. The relatively 
long half-life in combination with monovalent interaction makes this non-pathogenic antibody format superior 
to Fab fragments7, post-exchange IgG411 or silenced IgG1 formats44 and suitable for clinical applications in MG.
Without covalent disulfide linkages in the hinge region, human IgG4 half-molecules are non-covalently 
associated through relatively weak interactions at the CH3-CH3 interface24, 45, 46. As a consequence, monovalent 
IgG4Δhinge molecules are still able to dimerize in a concentration dependent manner and high target expres-
sion levels can promote local dimerization and induce crosslinking. Although this effect is not evident from 
the results, the 4% blocking observed in 1 animal that only received IgG4Δhinge, compared to untreated ani-
mals, could thus be explained. Likewise, local IgG concentrations in the endosomes could promote IgG4Δhinge 
dimerization and increase the avidity for FcRn. This could explain the discrepancy between the clearance rate of 
IgG4 half-molecules observed in Balb/c mice in our study and that reported by Wilkinson et al.46, i.e. a 2.5-fold 
faster clearance of IgG4Δhinge relative to wild-type IgG4 in this study, compared to a 10–20-fold faster clear-
ance for IgG4 half-molecules engineered to be more monovalent. Although the pharmacokinetic (PK) profile of 
IgG4Δhinge is superior to that of Fab fragments, functionally monovalent formats with regular IgG PK would 
still be preferred. A non-glycosylated one-armed format like the one described for c-Met47, a non-activating func-
tionally monovalent bispecific IgG format (e.g. containing one dummy arm)48, or even a non-activating bispecific 
IgG containing two non-overlapping AChR-specific arms that supplement each other in blocking auto-antibodies 
but incapable of inducing AChR-crosslinking, would be worth investigating.
In our study we used a monoclonal antibody to induce disease in our model, while in patients the AChR autoan-
tibodies are polyclonal49. The competition between the therapeutic IgG4Δhinge-637 antibody and poly-clonal 
patient IgG is variable, based on experiments with the scFv-6379 and Fab-6377. Such an in vitro competition 
assay could be used to identify patients that might benefit from IgG4Δhinge blocker antibodies prior to therapy. 
Moreover, the blocker therapy could be extended with a number of other human AChR monoclonal antibodies 
that are now available7, 49–52.
With the present study efficacy of the therapy could not be tested in a model of severe clinical disease symp-
toms since we used non-human primates. Therefore our results do not allow definitive conclusions about the 
safety and efficacy in severe disease, e.g. a myasthenic crisis. Since the NMJ has a remarkable capacity for regen-
eration and the AChR has a high turnover of ~1 week, we believe that even during pre-existing disease it is mean-
ingful to prevent antibody-binding to newly-formed AChRs.
Specific conditions in which MG blocker therapy might potentially be beneficial include drug-resistant MG, 
neonatal myasthenia or arthrogryposis, where passive transfer occurs from mother to child via placental transfer. 
Furthermore, the IgG4Δhinge format might be useful for treatment of other antibody-driven autoimmune chan-
nelopathies53, such as neuromyelitis optica44, or organ-specific AIDs in general, where complement activation or 
antigenic modulation are major pathogenic mechanisms.
Taken together, these results demonstrate that IgG4Δhinge shows good therapeutic efficacy in a 
well-characterized model for PTMG in rhesus monkeys, which is highly supportive of further investigations into 
the development of antigen-specific therapies.
Materials and Methods
Cells. FreeStyle™ 293 F (HEK-293F) and FreeStyle™ CHO-S (CHO-S) cells were cultured in FreeStyle™ 293 
expression medium and FreeStyle™ CHO expression medium, respectively (Invitrogen, Carlsbad, CA). TE671 
(human rhabdomyosarcoma54) cells were cultured in IMDM (Gibco) supplemented with 10% (v/v) heat-inac-
tivated FCS (Bodinco, Alkmaar, the Netherlands), 1% (v/v) penicillin/streptomycin (Gibco), 1 mM pyruvate 
(Gibco) and 2.5 μM dexamethasone (Sigma).
Cloning and expression of antibodies. Construction of expression vectors for IgG1-637 (pIgG-637) 
and IgG4-637 (pTomG4MG and pConLamMG) have been described previously11. For the construction of the 
IgG4Δhinge-637 heavy chain expression vector, the IgG4-637 heavy chain coding sequence was codon opti-
mized with deletion of amino acid residues 216-ESKYGPPCPSCP-230 (EU-numbering conventions are used 
throughout the manuscript), constituting the genetic IgG4 hinge exon. The whole construct was synthesized de 
novo by Geneart AG (Regensburg, Germany) and cloned in expression vector pEE6.4 (Lonza Biologics, Slough, 
UK), resulting in pHG-MG.
All antibodies were produced under serum-free conditions (FreeStyle™ medium) by cotransfecting relevant 
heavy and light chain expression vectors in HEK-293F cells, using 293fectin (Invitrogen), or CHO-S cells using 
FreeStyle™ MAX Reagent (Invitrogen), both according to the manufacturer’s instructions. Stable CHO-K1SV 
clones expressing IgG1-637, IgG4-637 or IgG4Δhinge-637 were obtained after selection with 50 μM MSX.
Antibodies were purified by Protein A affinity chromatography (rProtein A FF, GE Healthcare, Uppsala, 
Sweden), dialyzed overnight to PBS and filtered-sterilized over 0.2 µM dead-end filters. Concentration of purified 
IgGs was determined by nephelometry and absorbance at 280 nm. Purified proteins were analyzed by SDS-PAGE, 
mass spectrometry and glycoanalysis. Batches of IgG were tested by size-exclusion chromatography and shown to 
be at least 94% monomeric. Endotoxin levels of batches used in vivo were below 0.1 EU/mg IgG.
Antigenic modulation of AChR. Antibody-induced degradation of surface AChR (antigenic modulation) 
was measured as described11. In short, confluent TE671 cells were incubated for 3 h at 37 °C with serial dilutions 
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of IgG1-637, IgG4Δhinge-637, human intravenous immunoglobulin (IVIg; Immunoglubulin I.V., Sanquin, the 
Netherlands). The antibodies were diluted in DMEM containing 40 μM cycloheximide (blocking de novo AChR 
synthesis). After washing of the cells, remaining AChR expression was determined by incubating for 1 h at 37 °C 
with an excess of 125I-labeled α-bungarotoxin in the same medium (without antibody), washing three times with 
PBS and assessing the amount of radioactivity bound. Nonspecific binding was measured by incubating cells with 
unlabeled α-bungarotoxin prior to incubation with 125I-labeled α-bungarotoxin.
Passive transfer myasthenia gravis in rhesus monkeys. Experiments were approved by the insti-
tutional ethical Committee on Animal Welfare (protocol DEC-590 BPRC) of the Biomedical Primate Research 
Center (Rijswijk, the Netherlands). All animal experimental procedures complied with applicable guidelines, reg-
ulations and laws of the Netherlands. Female rhesus monkeys (Macaca mulatta) of 3.5 to 8.0 kg were pre-screened 
for the presence of preexisting anti-human IgG responses and were found negative (data not shown). Antibodies 
were given as three doses (injected on consecutive days) to guarantee animal safety and enable acute therapy in 
case of a myasthenic crisis12. Intravenous injections with IgG1-637 and IgG4Δhinge-637 were well tolerated and 
no acute adverse effects were observed. MG was induced by administration of IgG1-637 at doses of 1.7 mg/kg/day 
resulting in a total cumulative dose of 5 mg/kg. The effect of IgG4Δhinge-637 was tested alone or in combination 
with IgG1-637 and was administered 6 hours prior to each IgG1-637 injection at 10 mg/kg/day (total cumulative 
dose of 30 mg/kg). In the case where IgG4Δhinge-637 was tested alone, a dose of saline was administered instead 
of the IgG1-637. Whole blood samples were taken on different days and collected in clot activator tubes with gel 
separator (Greiner) and tubes containing a mix of protease inhibitors and anti-coagulation factors55. The clot 
activator tubes were centrifuged at room temperature for 10 min at 2000 × g. The resulting serum was collected 
and used for clinical chemistry or stored at −80 °C. The tubes containing protease inhibitors and anti-coagulation 
factors were centrifuged at room temperature for 10 min at 1000 × g, no brake. The resulting plasma was ali-
quoted into 3 tubes and stored at −80 °C. Each animal was used for an experiment only once to avoid the effect of 
a primate anti-human antibody response. In total fifteen monkeys (Supplementary Table 1) were used which all 
survived the experiments and were not sacrificed for analysis.
Clinical observation. Body weight was recorded each day the animals were sedated. Clinical muscle weak-
ness was defined by at least two of the following symptoms: difficulty to walk, difficulty to climb, difficulty to eat 
or swallow, drooping of the eyelids (ptosis), more than 5% weight loss. If any one of the aforementioned tasks 
(walking, climbing or eating/swallowing) could not be performed at all, weakness was also demonstrated. In this 
study, none of these symptoms were observed.
Analysis of neuromuscular transmission by single fiber electromyography (SFEMG). Rhesus 
monkeys were anesthetized with 10 mg/kg ketamine without the use of muscle relaxants. Stimulated SFEMG 
was performed in the orbicularis oculi (OO) muscles. As a stimulation electrode, a monopolar needle electrode 
was placed lateral to the lateral canthus of the eye to stimulate facial nerve branches. Stimulus duration was 
0.02 ms and stimulus intensity was increased until a visible movement of the upper eyelid was obtained during 
3 Hz stimulation. The recording SF-needle electrode was placed in the orbital part of the OO. As soon as muscle 
fiber potentials were obtained, stimulation frequency was increased to 10 Hz. All examinations recorded 68–100 
sweeps (average was 99.7) of >20 muscle fiber action potentials (MFAPs). Jitter is the measurement of variation 
of the inter-potential interval. Jitter values were expressed as the mean consecutive difference (MCD), which is 
defined as the mean time interval between the triggered potential and the time-locked single muscle fiber action 
potential. Blockings are defined as the absence of a muscle fiber action potential after nerve stimulation. SFEMG 
was performed at baseline and repeated seven days after administration of antibodies.
Measurement of decrement of the compound muscle action potential (CMAP). Decrement of 
CMAP was measured in the extensor digitorum brevis muscle upon stimulation of the peroneal nerve below 
the fibular head. Recording and stimulation was performed with surface electrodes. The reference electrode was 
placed distal to the active recording electrode at a distance of 3 to 4 cm. Using single stimuli of 0.1 ms duration 
and gradually increasing intensity, the current intensity was determined at which a maximal CMAP amplitude 
was reached. To detect a decremental response, ten stimuli with a 20 to 30% higher stimulus strength (supramax-
imal) were given at 3, 5 and 10 Hz. Test results had to be reproducible for at least three consecutive measurements 
and were considered positive when both the amplitude and the area of the negative peak op the CMAP showed a 
decrement of at least 10%. Average decrement values of individual animals were also analyzed statistically at the 
level of experimental groups.
Intercostal muscle biopsies. Biopsies were taken before and seven days after the first injection of anti-
body, under general anesthesia (induced with ketamine and maintained with endotracheal isoflurane/halothane/
oxygen) and analgesia (Temgesic, 0.3 mg/mL buprenorfine base, Schering Plough B.V.), as originally described 
for human muscle56. Pieces of the external layer of parasternal intercostal muscle were prepared free from the 
internal layer by means of small non-traumatic forceps through an incision between the sixth and seventh rib. 
The biopsy was then taken carefully from rib-to-rib with pieces of periosteum attached. Subsequently, intercostal 
muscle biopsies were cut into fragments of 3 mm diameter. For electron microscopic analysis, biopsies submerged 
in fixation buffer (0.1 M phosphate buffer supplemented with 2.5% glutaraldehyde, pH 7.4) and stored at 4 °C for 
up to seven days. For immunofluorescent analysis, biopsies were frozen on melting isopentane and subsequently 
stored at −80 °C.
Electron microscopy. Glutaraldehyde-fixed biopsies were then postfixed with 1% osmiumtetroxide (in 
0.1 M phosphate buffer, pH 7.4), dehydrated through a graded ethanol series and embedded in epoxy resin 
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(Glycid ether 100, Serva). Endplates were located in toluidine blue-stained semi-thin sections. Ultra-thin sections 
from selected areas were contrasted with uranyl acetate and lead citrate and analyzed with a Philips CM 100 elec-
tron microscope. Quantitative morphometric analysis was performed as previously described57 and calculated as 
the postsynaptic membrane length divided by the presynaptic membrane length (folding index).
Postsynaptic widening of the primary or secondary cleft was scored blindly. The definitions for the ‘cleft wid-
ening score’ were: severely widened clefts (primary or secondary) = 0; widened clefts (primary or secondary) = 1, 
normal or very slightly widened clefts (primary or secondary) = 2, clearly intact postsynaptic membrane = 3. 
Four to twenty-five (median = ten) neuromuscular junctions were scored per monkey for postsynaptic widening. 
The percentage of widened postsynaptic clefts was calculated per monkey. In this calculation scores of 0 (severely 
widened clefts) and 1 (widened clefts) were regarded as proof of postsynaptic cleft widening, while scores of 2 
(normal or very slightly widened clefts) and 3 (clearly intact postsynaptic membrane) were considered to have 
no cleft widening.
Immunofluorescence staining, microscopy and quantitative analysis. Biopsies were cryo-
sectioned (10 µm) and stored at −80 °C. Sections were fixed with ice-cold acetone for 10 min. The membrane 
attack complex (MAC) C5b-9 was stained mouse mAb AE11 (1:50, Hycultbiotech, the Netherlands) for one 
hour. Immunofluorescent triple staining was performed for one hour with FITC-conjugated sheep anti-human 
IgG (the Binding Site; minimal cross-reaction with monkey immunoglobulins), and Alexa-647-conjugated 
alpha-bungarotoxin (1:300, Thermo Fischer Scientific, catalog number B35450) and a Alexa Fluor 594 conjugated 
goat anti-mouse IgG (H + L) secondary antibody (1:500, Thermo Fischer Scientific, catalog number A-11005) 
which had minimal cross-reaction to other immunoglobulins used in the staining procedure or present in the 
biopsies. Washes were performed with PBS containing 0.05% Triton-X100 (3 × 5 min). Sections were mounted 
with 80% glycerol in PBS. Fluorescent photomicrographs of endplate regions were acquired using µManager 
software 2.0 on an BX51WI spinning disk confocal fluorescence microscope (Olympus, Hamburg, Germany) 
with an Hamamatsu EM-CCD C9100 digital camera. Fluorescent intensities of endplates were analyzed using 
imageJ software (www.imagej.nih.gov/ij/) as described58–60. All staining procedures and fluorescent analysis were 
performed on coded samples by a blinded investigator.
Statistical analysis. Unless otherwise indicated, differences between treatment groups were tested for sig-
nificance by a linear mixed model using SAS software (SAS Institute Inc., Cary, NC). In this model subject was 
included as a random effect and group and/or time as fixed effects. Compound symmetry was used as variance/
covariance structure. The binary cleft widening data were analyzed by general estimating equations for longitudi-
nal binary outcome data. P-values below 0.05 were considered significant.
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